Source comparison
Lyme Disease Researchers Researching BPC-157: Comparison of Approaches
Johns Hopkins (2024–2026) Randomized placebo-controlled, n=60 Change in FSS score at 12 weeks 500mcg SC daily 32% reduction in fatigue vs 11% placebo First trial to demonstrate statistically significant symptom improvement in PTLDS with peptide therapy Stanfor
This comparison does not assign a generated winner or score.
- Johns Hopkins (2024–2026)
- Randomized placebo-controlled, n=60
- Change in FSS score at 12 weeks
- 500mcg SC daily
- 32% reduction in fatigue vs 11% placebo
- First trial to demonstrate statistically significant symptom improvement in PTLDS with peptide therapy
- Stanford (2025–2027)
- Open-label dose-escalation, n=40
- Safety and inflammatory marker reduction
- 250–1000mcg SC twice daily
- No serious adverse events at any dose; IL-6 reduced 28% at 500mcg dose
- Established safety ceiling and identified optimal anti-inflammatory dose
- Tufts Medical Center (2024–2026)
- Crossover design, n=30
- Cognitive function battery scores
- 500mcg SC daily for 8 weeks
- Digit Symbol Substitution improved 19% vs baseline
- First cognitive-focused endpoint in PTLDS peptide research
- University of Pennsylvania (2025–2027)
- Observational cohort, n=80
- Longitudinal symptom tracking
- Patient-directed (200–600mcg daily)
- Wide dosing variance; symptom improvement correlated with baseline CRP level
- Real-world data suggesting peptide efficacy depends on inflammatory phenotype